Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Latest Pulmonology Stories

2013-10-10 16:24:10

ALBANY, New York, October 10, 2013 /PRNewswire/ -- New Report Added in ResearchMoz Reports Database Asthma Therapeutics Market to 2019 - Breakthrough Biologics to Enhance Treatment of Severe Asthma and Drive Market Growth ResearchMoz announces that it has published a new study Asthma Therapeutics Market to 2019 - Breakthrough Biologics to Enhance Treatment of Severe Asthma and Drive Market Growth...

2013-10-07 09:22:06

In a study published in published in EMBO Molecular Medicine, a Dartmouth researcher found that dying heart cells are kept alive with spikes of oxygen. During a heart attack when the flow of oxygen-rich blood to a section of the heart is interrupted, and not quickly restored, heart muscle begins dying. Deprived of oxygen and other essential nutrients, cell death continues occurring over a period of time leading to progressive loss of heart function and congestive heart failure. Current...

2013-10-01 15:37:46

To address the global phenomenon of disparities in respiratory health, the American Thoracic Society and the European Respiratory Society have released an official policy statement in which each pledges its commitment to reducing health disparities between the lowest and highest socioeconomic groups by continuing or initiating work with leaders from governments, academia, and other organizations to promote scientific inquiry and training, disseminate medical information and best practices,...

2013-09-26 08:26:53

MOUNTAIN VIEW, Calif., Sept. 26, 2013 /PRNewswire/ -- PneumRx, Inc., a leader in interventional pulmonology, announced that over 1500 procedures have been performed using the RePneu Lung Volume Reduction Coil (LVRC) System for patients with severe emphysema. (Logo: http://photos.prnewswire.com/prnh/20120514/SF06703LOGO) The RePneu LVRC is a minimally invasive device intended to improve lung function, exercise capacity and quality of life in emphysema patients by bronchoscopically...

2013-09-25 23:35:56

Avail is conducting a 24-week study to evaluate the effect of a once-daily experimental inhalation therapy on arterial stiffness compared to a placebo and another drug in subjects with Chronic Obstructive Pulmonary Disease (COPD). DeLand, Florida (PRWEB) September 25, 2013 *To see if you qualify for this COPD Clinical Trial in Florida, visit Avail Clinical Research on the web (http://www.availclinical.com) or contact us directly at (386) 785-2404. There is no cost to participate, no...

2013-09-24 12:28:28

NEW YORK, Sept. 24, 2013 /PRNewswire/ -- In support of Pulmonary Fibrosis Awareness Month, Boehringer Ingelheim and the Coalition for Pulmonary Fibrosis (CPF) are teaming up to raise awareness of idiopathic pulmonary fibrosis, or IPF, a progressive and fatal disease that causes permanent scarring of the lungs, difficulty breathing, and prevents oxygen from getting to the body. This collaboration also features actress Rose McGowan, who is best known for her leading role in the hit...

2013-09-24 08:31:11

BRISBANE, Calif., Sept. 24, 2013 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that Andrew Powell has joined InterMune as Executive Vice President, General Counsel and Corporate Secretary. (Logo: http://photos.prnewswire.com/prnh/20120827/SF62570LOGO) Mr. Powell will be responsible for managing the company's legal affairs. He will report to Dan Welch, Chairman, Chief Executive Officer and President of InterMune. Mr. Welch said, "Andrew brings experience in many...

2013-09-23 08:22:41

-- Adempas® (riociguat) offers new hope for patients suffering from chronic thromboembolic pulmonary hypertension (CTEPH) -- Adempas® is now available in Canada as the first and only drug indicated to manage the treatment of chronic thromboembolic pulmonary hypertension (CTEPH)1,2 TORONTO, Sept. 23, 2013 /CNW/ - Bayer Inc. announced today the Health Canada approval of Adempas® (riociguat). Adempas® is the first drug...

2013-09-20 00:20:36

Patients encouraged to embrace digital advances which allow "networking to a degree that previously might not have been possible" BRISBANE, Calif., Sept. 20, 2013 /PRNewswire/ -- This year's IPF World Week (September 21-29) sees healthcare professionals, patient advocacy groups, people living with idiopathic pulmonary fibrosis (IPF), who have an estimated median survival time of two to five years,(i )and their families calling for an integrated approach to further strengthen the...

2013-09-17 08:31:07

REHOVOT, Israel, September 17, 2013 /PRNewswire/ -- Israeli biomed company AIT (Advanced Inhalation Therapies Ltd.), a leader in the development of nitric oxide therapeutics for the treatment of infectious respiratory diseases, announced today the appointment of Hugh M. O'Brodovich, M.D.,to its scientific advisory board. Dr. O'Brodovich holds the position of Arline & Pete Harman Professor & Chair at the Department of Pediatrics Stanford School of Medicine. Dr....


Latest Pulmonology Reference Libraries

0_f9fe10c6664d20ba0d9091907b66a65f
2011-01-05 16:00:36

Human parainfluenza viruses, belonging to the paramyxovirus family, are a group of four distinct serotypes of enveloped single-stranded RNA viruses. They are the second most common cause of lower respiratory tract infection in younger children. Many times the host has repeat infections throughout life with symptoms that may include upper respiratory tract illness or more commonly, a cold and sore throat. It can also cause severe pneumonia in immunosuppressed people. There is currently no...

More Articles (1 articles) »